QUCHMIC
Chemical compound
From Wikipedia, the free encyclopedia
QUCHMIC (named using EMCDDA naming standards,[1] but regularly mis-named QUCHIC[nb 1]), also known as BB-22, SGT-32, or quinolin-8-yl 1-cyclohexylmethyl-1H-indole-3-8-carboxylate, is a designer drug offered by online vendors as a cannabimimetic agent, and was first detected being sold in synthetic cannabis products in Japan in early 2013,[2] and subsequently also in New Zealand.[3]
- CA: Schedule II
- DE: Anlage II (Authorized trade only, not prescriptible)
- NZ: Temporary Class
- UK: Class B
| Clinical data | |
|---|---|
| Other names | BB-22; SGT-32; quinolin-8-yl 1-cyclohexylmethyl-1H-indole-3-8-carboxylate |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H24N2O2 |
| Molar mass | 384.479 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The structure of QUCHMIC appears to use an understanding of structure-activity relationships within the indole class of cannabimimetics, although its design origins are unclear. QUCHMIC, along with QUPIC, QUFUBIC, 2F-QMPSB and NA-PINAC, represent a structurally unusual synthetic cannabinoid chemotype since they contain an ester linker at the indole 3-position rather than the precedented ketone of JWH-018 and its analogues, or the amide of SDB-001 and its analogues.
Pharmacology
QUCHMIC acts as a full agonist with a binding affinity of 0.217 nM at CB1 and 0.338 nM at CB2 cannabinoid receptors.[4]
See also
Notes
- The compound QUCHIC (quinolin-8-yl 1-cyclohexyl-1H-indole-3-8-carboxylate) has never been detected